Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System

Blood (2021) 138 (Supplement 1): 3858.

https://doi.org/10.1182/blood-2021-151672

Published: 2021

Journal Articles

Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Caitlin L. Costello, MD, Adam D. Cohen, MD, Krina K. Patel, MD, Syed S Ali, MD, Jesus G. Berdeja, MD, Nina Shah, MD, Siddhartha Ganguly, MD, Mehmet Hakan Kocoglu, MD, Mehrdad Abedi, MD, Eric M. Ostertag, MD PhD, Chris E Martin, PhD, Majid Ghoddussi, PhD, Devon J Shedlock, PhD, Joanne McCaigue, M.S., Hamid Namini, PhD, Sreeni Yalamanchili, Matthew A. Spear, MD, Tara K. Gregory, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142695

Published: 2020

Journal Articles

Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)

Caitlin L. Costello, MD, Tara K. Gregory, MD, Syed Abbas Ali, MD, Jesus G. Berdeja, MD, Krina K. Patel, MDMSc, Nina D. Shah, MD, Eric Ostertag, Chris Martin, Majid Ghoddusi, PhD DVM, Devon J Shedlock, PhD, Matthew A. Spear, MD, Robert Z. Orlowski, MD, PhD, Adam D. Cohen, MD

Blood (2019) 134 (Supplement_1): 3184.

https://doi.org/10.1182/blood-2019-129562

Published: 2019

Journal Articles

Efficacy and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Tara Gregory, MD, Adam D. Cohen, MD, Caitlin L. Costello, MD, Syed Abbas Ali, MD, Jesus G. Berdeja, MD, Eric M Ostertag, MD PhD, Christopher Martin, PhD, Devon J Shedlock, PhD, Michelle Lynn Resler, BS, Matthew A. Spear, MD, Robert Z. Orlowski, MD PhD, Krina K. Patel, MDMSc

Blood (2018) 132 (Supplement 1): 1012.

https://doi.org/10.1182/blood-2018-99-111419

Published: 2018

Journal Articles

Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Paul G. Richardson, MD, Andrew Spencer, MD, Paul Cannell, MBBS, FRCPA, FRACP, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Laurence Catley, MBBS, FRCPA, FRACP, Craig Underhill, MBBS, FRACP, Todd M. Zimmerman, MD, Craig C. Hofmeister, MD, Andrzej J Jakubowiak, MD, PhD, Jacob P. Laubach, MD, Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Ana Lay, Sandra Wear, RN, G. Kenneth Lloyd, PhD, Alison L. Hannah, MD, Steve Reich, MD, Matthew A. Spear, MD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 302.

https://doi.org/10.1182/blood.V118.21.302.302

Published: 2011

Journal Articles

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM).

Paul Richardson, M.D, Craig Hofmeister, MD, Andrzej Jakubowiak, MD, PhD, Todd M. Zimmerman, MD, Matthew A. Spear, MD, Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Susan L. Kelly, MD, Saskia Neuteboom, PhD, Gillian F Cropp, MSc, G. Kenneth Lloyd, PhD, Alison L. Hannah, MD, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 431.

https://doi.org/10.1182/blood.V114.22.431.431

Published: 2009

Journal Articles

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052.

Andrew Spencer, Michael Millward, MD, Paul Mainwaring, MD, Simon Harrison, MD, Laurence Catley, MBBS, FRCPA, FRACP, Amanda Townsend, MD, Shawgi Sukumaran, MD, Angie M. Longenecker, RN, BSN, Michael A. Palladino, PhD, G. Kenneth Lloyd, PhD, Saskia Neuteboom, PhD, Peeter Padrik, MD, Matthew A. Spear, MD, Timothy Price, MD

Blood (2009) 114 (22): 2693.

https://doi.org/10.1182/blood.V114.22.2693.2693

Published: 2009

Journal Articles

Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma

Paul Richardson, MD, Craig C. Hofmeister, MD, Todd M. Zimmerman, MD, Asher Alban Chanan-Khan, MD, Matthew A. Spear, MD, Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Gillian Cropp, MS, G. Kenneth Lloyd, PhD, Sandra Wear, Alison L. Hannah, MD, Kenneth C Anderson, MD

Blood (2008) 112 (11): 2770.

https://doi.org/10.1182/blood.V112.11.2770.2770

Published: 2008

Journal Articles

Clinical Trial of NPI-0052 (2nd generation proteasome inhibitor) in Patients Having Advanced Malignancies with Expanded RP2D Cohorts in Lymphoma and CLL

Timothy Price, MD, Peeter Padrik, MD, Amanda Townsend, MD, Paul Mainwaring, MD, Lawrence Catley, MD, Angie M. Longenecker, RN, BSN, Gillian Cropp, MS, Michael A. Palladino, PhD, G. Kenneth Lloyd, PhD, Matthew A. Spear, MD, Michael Millward, MD

Blood (2008) 112 (11): 4934.

https://doi.org/10.1182/blood.V112.11.4934.4934

Published: 2008

Journal Articles

First-in-Human Phase 1 Dose Escalation Study of NPI-0052, a Novel Proteasome Inhibitor, in Patients with Lymphoma and Solid Tumor

Paul A. Hamlin, MD, Carol Aghajanian, M.D., David Hong, M.D., Anas Younes, M.D., Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Gillian Cropp, MS, G. Kenneth Lloyd, PhD, Alison L. Hannah, MD, Matthew A. Spear, MD, Razelle Kurzrock, MD

Blood (2008) 112 (11): 4939.

https://doi.org/10.1182/blood.V112.11.4939.4939

Published: 2008

Journal Articles

Phase 1 Clinical Trial of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors.

Razelle Kurzrock, MD, Paul Hamlin, M.D., Anas Younes, M.D., David Hong, M.D., Michael Gordon, M.D., Matthew A. Spear, M.D., Michael A. Palladino, Ph.D., G. Kenneth Lloyd, Ph.D., Angie M. Longenecker, R.N., Saskia T.C. Neuteboom, Ph.D., Gillian F. Cropp, M.S., Alison Hannah, M.D., Carol Aghajanian, M.D.

Blood (2007) 110 (11): 4504.

https://doi.org/10.1182/blood.V110.11.4504.4504

Published: 2007

NARROW

Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System

Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)

Efficacy and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM).

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052.

Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma

Clinical Trial of NPI-0052 (2nd generation proteasome inhibitor) in Patients Having Advanced Malignancies with Expanded RP2D Cohorts in Lymphoma and CLL

First-in-Human Phase 1 Dose Escalation Study of NPI-0052, a Novel Proteasome Inhibitor, in Patients with Lymphoma and Solid Tumor

Phase 1 Clinical Trial of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only